part 2
by: soldier30 11/12/01 09:05 pm
Msg: 1301 of 1302
ú Abstracts from the upcoming ASH meeting show encouraging data from studies
with AlloMune; BTRN's partner, Gambro BCT, will be sponsoring a symposium at
ASH. The abstracts from the upcoming American Society of Hematology (ASH)
meeting were released earlier this week. Two studies involving the AlloMune
system for cancer have shown some encouraging early results. The first
evaluated the impact of donor lymphocyte infusions in 46 patients with advanced
hematologic malignancies treated with the AlloMune protocol. In bone marrow
transplant for refractory blood cancers, donor lymphocyte infusion (DLI) is a
technique to boost the white blood cells of the recipient to potentially
increase the response rate. In this study, 18 patients received DLI and 50%
(9/18) had a complete response. In the patients who did not receive DLI, 25%
(7/28) had a complete response. A second abstract details the durable responses
in another 19 refractory aggressive lymphoma patients treated with the AlloMune
protocol (which includes MEDI-507). Forty-two percent (8/19) of patients
achieved either a complete response (5/19, 26%) or a partial response (3/19,
16%). Five (26%) of these patients are still alive and progression free at 13 -
52 months post-transplant. We are particularly encouraged by the high level of
response rates in those patients receiving DLI and the durability of these
responses.
BioTransplant's marketing partner for the Eligix cell separation devices, Gambro
BCT, will sponsor a symposium to discuss cell separation and its role in
enhancing patient outcomes through graft engineering on Sunday, December 9,
2001, at 6 p.m. at the Rosen Plaza Hotel in Orlando. |
